

**AMENDMENTS TO THE CLAIMS (AS ON AMENDED SHEETS ANNEXED TO IPER)**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A composition consisting of :

a first sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition during a period of at least about one month at a rate sufficient to induce and maintain chemical castration of a male patient, and

a second sustained release formulation of an estrogenic composition capable of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the hot flashes that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient,

characterised in that said second sustained release formulation releases an estrogenic composition under a profile comprising at least a first initial phase and a second phase, the release of the estrogenic composition in the course of said second phase being at a rate between about 10 and 100 mg of estradiol equivalent per day, the release of the estrogenic composition in the course of said first initial phase never exceeding 5 times the daily release of the estrogenic composition occurring during said second phase.

2. (original) The composition according to claim 1, characterised in that said first sustained release formulation of a gonadotropin hormone releasing hormone composition is capable of releasing the gonadotropin hormone releasing hormone composition at a rate between about 10 and about 1,000 µg per day.

3. (original) A composition consisting:

a first sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing

hormone composition for a period of at least about one month at an average rate between about 10 and 1,000 µg per day, and

a second sustained release formulation of an estrogenic composition capable of releasing the estrogenic composition under a profile comprising at least a first initial phase and a second phase, the release of the estrogenic composition in the course of said second phase being at a rate between about 10 and 100 mg of estradiol equivalent per day, the release of the estrogenic composition in the course of said first initial phase never exceeding 5 times the upper daily release of the estrogenic composition occurring during said second phase.

4. (currently amended) The composition according to ~~any of the preceding claims~~ claim 1, characterised in that the gonadotropin hormone releasing hormone composition is selected from the group consisting of gonadotropin hormone releasing hormone, agonists of gonadotropin hormone releasing hormone, antagonists of gonadotropin hormone releasing hormone and mixtures thereof.

5. (currently amended) The composition according to ~~claims 1, 2, or 3~~ claim 1, characterised in that the gonadotropin hormone releasing hormone composition is a gonadotropin hormone releasing hormone agonist selected from the group consisting of leuprorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histerelin, gonadorelin, and salts and mixtures thereof.

6. (currently amended) The composition according to ~~claims 1, 2, or 3~~ claim 1, characterised in that the estrogenic composition is selected from the group consisting of chlorotrianisene, dienestrol, diethylstilbestrol, diethylstilbestrol dipropionate, diethylstilbestrol monobenzyl ether, equilelinin, equilelinin sulfate, estetrol, estradiol, (3a,17b)-estr-4-ene-3,17-diol, estriol, estriol hemisuccinate, estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, tamoxifen, toremifene, raloxifene, lasofoxifene and mixtures thereof.

7. (currently amended) The composition according to ~~claims 1, 2, or 3~~ claim 1, characterised in that the gonadotropin releasing hormone composition is triptorelin or a salt thereof and the estrogenic composition is estradiol.

8. (original) The composition of claim 7, characterised in that triptorelin, or a triptorelin salt, is released at a rate of about 100 µg per day and estradiol is released at a rate between about 25 and 50 µg per day.

9. (currently amended) A method for the treatment of prostate cancer comprising:

~~Administering~~ administering to a patient suffering from prostate cancer a sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition for a period of at least about one month at a rate sufficient to induce and maintain chemical castration of the patient, and

~~Simultaneously~~ simultaneously administering to the patient a sustained release formulation of an estrogenic composition capable of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the hot flashes that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient.

10. (currently amended) A method for the treatment of prostate cancer comprising:

~~Administering~~ administering to a patient suffering from prostate cancer a sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition for a period of at least about one month at an average rate between about 10 and 1,000 µg per day, and

~~Simultaneously~~ simultaneously administering to the patient a sustained release formulation of an estrogenic composition under a profile comprising at least a first initial phase and a second phase, the release of the estrogenic composition in the course of

said second phase being at a rate between about 10 and 100 mg of estradiol equivalent per day, the release of the estrogenic composition in the course of said first initial phase never exceeding 5 times the upper daily release of the estrogenic composition occurring during said second phase.

11. (currently amended) A method for the treatment of prostate cancer comprising:

~~Administering~~ administering to a patient suffering from prostate cancer a sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition for a period of at least about one month at an average rate between about 10 and 1,000 µg per day, and

~~Simultaneously~~ simultaneously administering to the patient a sustained release formulation of an estrogenic composition under a profile comprising at least a first initial phase and a second phase, the release of the estrogenic composition in the course of said second phase being at a rate between about 10 and 100 mg of estradiol equivalent per day, the release of the estrogenic composition in the course of said first initial phase never exceeding 5 times the upper daily release of the estrogenic composition occurring during said second phase.

12. (currently amended) A method as in ~~claims 9, 10 or 11~~ claim 9, wherein the gonadotropin hormone releasing hormone composition is selected from the group consisting of gonadotropin hormone releasing hormone, agonists of gonadotropin hormone releasing hormone, antagonists of gonadotropin hormone releasing hormone and mixtures thereof.

13. (currently amended) A method as in ~~claims 9, 10 or 11~~ claim 9, wherein the gonadotropin hormone releasing hormone composition is a gonadotropin hormone releasing hormone agonist selected from the group consisting leuprorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histerelin, gonadorelin, and salts and mixtures thereof.

14. (currently amended) A method as in ~~claims 9, 10 or 11~~ claim 9, wherein the estrogenic composition is selected from the group consisting of chlorotrianisene, dienestrol, diethylstilbestrol, diethylstilbestrol dipropionate, diethylstilbestrol monobenzy ether, equilelinin, equilelinin sulfate, estetrol, estradiol, (3a,17b)-estr-4-ene-3,17-diol, estriol, estriol hemisuccinate, estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quineestrol, tamoxifen, toremifene, raloxifene, lasofoxifene and mixtures thereof.

15. (currently amended) A method as in ~~claims 9, 10 or 11~~ claim 9, wherein the gonadotropin releasing hormone composition is triptorelin or a salt thereof and the estrogenic composition is estradiol.

16. (original) A method according to claim 15, wherein triptorelin, or a triptorelin salt, is released at a rate of about 100 µg per day and estradiol is released at a rate between about 25 and 50 µg per day.

17. (currently amended) A method as in ~~claims 9, 10 or 11~~ claim 9, wherein the composition is administered by a subcutaneous, intramuscular, or transdermal route.

18. (original) Use of a composition comprising:

a first sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition during a period of at least about one month at a rate sufficient to induce and maintain chemical castration of a male patient, and

a second sustained release formulation of an estrogenic composition capable of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the hot flashes that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient, said serum level in estradiol equivalent being less than about 50 pg/ml.

19. (original) Use of a composition comprising:

a first sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing the gonadotropin hormone releasing hormone composition for a period of at least about one month at an average rate between about 10 and 1,000 µg per day, and

a second sustained release formulation of an estrogenic composition capable of releasing the estrogenic composition under a profile comprising at least a first initial phase and a second phase, the release of the estrogenic composition in the course of said second phase being at a rate between about 10 and 100 mg of estradiol equivalent per day, the release of the estrogenic composition in the course of said first initial phase never exceeding 5 times the upper daily release of the estrogenic composition occurring during said second phase,

for the preparation of a medicament for treatment of prostate cancer in a patient suffering from prostate cancer, said first sustained release formulation and said second sustained release formulation being simultaneously administrated to said patient.

20. (currently amended) The use according to ~~any of the claims 18 or 19~~ claim 18, characterised in that the gonadotropin hormone releasing hormone composition is selected from the group consisting of gonadotropin hormone releasing hormone, agonists of gonadotropin hormone releasing hormone, antagonists of gonadotropin hormone releasing hormone and mixtures thereof.

21. (currently amended) The use according to ~~any of the claims 18 or 19~~ claim 18, characterised in that the gonadotropin hormone releasing hormone composition is a gonadotropin hormone releasing hormone agonist selected from the group consisting leuporelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histerelin, gonadorelin, and salts and mixtures thereof.

22. (currently amended) The use according to ~~any of the claims 18 or 19~~ claim 18, characterised in that the estrogenic composition is selected from the group consisting of chlorotrianisene, dienestrol, diethylstilbestrol, diethylstilbestrol dipropionate, diethylstilbestrol monobenzyl ether, equilelinin, equilelinin sulfate, estetrol,

estradiol, (3a,17b)-estr-4-ene-3,17-diol, estriol, estriol hemisuccinate, estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, tamoxifen, toremifene, raloxifene, lasofoxifene and mixtures thereof.

23. (currently amended) The use according to ~~any of the claims 18 or 19~~ claim 18, wherein the gonadotropin releasing hormone composition is triptorelin or a salt thereof and the estrogenic composition is estradiol.

24. (original) The use according to claim 23, wherein triptorelin, or a triptorelin salt, is released at a rate of about 100 µg per day and estradiol is released at a rate between about 25 and 50 µg per day.

25. (currently amended) The use according to ~~any of the claims 18 or 19~~ claim 18, wherein the composition is administered by a subcutaneous, intramuscular, or transdermal route.